In 2023 CISNET modeling, annual screening from ages 40 to 79 produced the greatest estimated mortality reduction at 41.7%, with 11.5 breast-cancer deaths averted and 230 life-years gained per 1,000 women screened; across the same 40 to 74 age range, annual screening was associated with an estimated 37% mortality reduction compared with 30% for biennial screening. The C01 cut points also rose for 2026, with the 5-Star threshold moving from 82% to 84%, so prior-year performance no longer maps to the same rating.
AAVBC's Breast Cancer Screening Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering the measure specification and HEDIS look-back window, why an order or scheduled appointment does not satisfy the numerator, reconciling mammograms completed at outside facilities, differences among USPSTF, ACOG, ACS, and ACR screening intervals, site-of-care optimization, abnormal-result follow-up, barriers and evidence-based solutions, and documentation that supports care. Grounded in current HEDIS specifications and major screening guidance, this guide supports consistent, individualized clinical decision-making, helping care teams convert a screening recommendation into completed care, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of C01 performance — moving far beyond quick-reference essentials. These guides provide an integrated review of measurement importance and impact, clinical integrations, technical details, challenges and barriers, strategies for team coordination and quality improvement as well as regulatory and financial considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of C01 performance and provide care teams with strategies to thrive within a value-based model.
In 2023 CISNET modeling, annual screening from ages 40 to 79 produced the greatest estimated mortality reduction at 41.7%, with 11.5 breast-cancer deaths averted and 230 life-years gained per 1,000 women screened; across the same 40 to 74 age range, annual screening was associated with an estimated 37% mortality reduction compared with 30% for biennial screening. The C01 cut points also rose for 2026, with the 5-Star threshold moving from 82% to 84%, so prior-year performance no longer maps to the same rating.
AAVBC's Breast Cancer Screening Quick Reference Guide equips primary care clinicians and care teams with a comprehensive, evidence-aligned reference covering the measure specification and HEDIS look-back window, why an order or scheduled appointment does not satisfy the numerator, reconciling mammograms completed at outside facilities, differences among USPSTF, ACOG, ACS, and ACR screening intervals, site-of-care optimization, abnormal-result follow-up, barriers and evidence-based solutions, and documentation that supports care. Grounded in current HEDIS specifications and major screening guidance, this guide supports consistent, individualized clinical decision-making, helping care teams convert a screening recommendation into completed care, with the clarity and continuity that durable outcomes require.
AAVBC’s Deep-Dive series offers a comprehensive, structured analysis of C01 performance — moving far beyond quick-reference essentials. These guides provide an integrated review of measurement importance and impact, clinical integrations, technical details, challenges and barriers, strategies for team coordination and quality improvement as well as regulatory and financial considerations. The Deep-Dives combine evidence-informed clinical guidance with practical operational tools to support a deeper understanding of C01 performance and provide care teams with strategies to thrive within a value-based model.
